It is expected to see Korean Companies to Have Solid Competitiveness on Development of Biosimilar Antibodies
While development of Biosimilar antibodies, a generic drug of the original biomedicine, is getting intensified, the Korean companies are expected to have solid competitiveness.
According to the data about the current development of Biosimilar antibodies, given by Hyun-Tae Kim, KDB Daewoo Financ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
